Shareholders to Vote on Repricing 13% of Outstanding Options Amidst Clinical Hold & Stock Collapse
AARD sits 55% above its 52-week low of $3.35.
Summary
Aardvark Therapeutics seeks shareholder approval to reprice 2.83 million underwater stock options for employees and executives, representing 13% of outstanding shares, following a significant stock price decline due to clinical trial setbacks and an FDA hold.
Key Events · Corporate Governance and Compliance · AARD
-
Option Repricing Proposal
Shareholders will vote on a proposal to reprice 2,833,944 outstanding stock options held by eligible employees and executive officers. These options represent approximately 13% of the company's issued share capital.
-
Significant Underwater Options
As of June 18, 2026, 99% of total outstanding options were 'underwater' (exercise price exceeded stock price), with an average exercise price of $10.71 compared to the then-current stock price of $3.93.
-
Executive Impact
The repricing includes options held by CEO Tien-Li Lee (793,951 shares), CFO Nelson Sun (304,094 shares), and CMO Manasi Jaiman (374,560 shares), all with significantly higher average exercise prices than the current market.
-
Response to Clinical Setbacks
This repricing follows a voluntary pause and subsequent full clinical hold by the FDA on the company's lead investigational drug, ARD-101, which caused a sharp decline in the stock price.
Analysis · AARD · Life Sciences
Aardvark Therapeutics is asking shareholders to approve repricing approximately 2.83 million underwater stock options for employees and executives, representing about 13% of outstanding shares. This move is a direct response to the company's stock price plummeting from $12.50 to $3.93 following a clinical hold on its lead drug ARD-101 and a securities fraud investigation. While framed as a critical retention strategy to keep key talent, the repricing effectively transfers significant value from existing shareholders to option holders by lowering strike prices, which is a dilutive event. This highlights the severe operational and financial distress the company is experiencing.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AARD was trading at $5.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113M. The 52-week trading range was $3.35 to $17.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.